54898-73-6 Usage
General Description
4-(aminomethyl)cyclohexane-1-carbonitrile, also known as Ambroxol hydrochloride, is a chemical compound with the molecular formula C10H16N2. It is widely used as a mucolytic agent to help break down and thin mucus in the airways, making it easier to cough up. Additionally, Ambroxol hydrochloride has been shown to have anti-inflammatory and antioxidant properties, making it a potentially useful compound for the treatment of respiratory conditions such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). It is often used in pharmaceuticals in the form of tablets, syrup, or inhalation solution. Overall, 4-(aminomethyl)cyclohexane-1-carbonitrile is a valuable chemical with therapeutic applications in respiratory medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 54898-73-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,8,9 and 8 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 54898-73:
(7*5)+(6*4)+(5*8)+(4*9)+(3*8)+(2*7)+(1*3)=176
176 % 10 = 6
So 54898-73-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H14N2/c9-5-7-1-2-8(6-10)4-3-7/h7-8H,1-5,9H2
54898-73-6Relevant articles and documents
Solid dispersions containing an apoptosis-inducing agent
-
Page/Page column 198, (2019/03/15)
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
